Improving the care of Lassa fever patients: re-evaluating the use of Ribavirin and characterising cardiovascular function
<p>Lassa fever is a viral haemorrhagic fever, endemic to several West African countries. Case fatality rates average 30% across the literature. Ribavirin, a broad-spectrum antiviral agent, has been used to treat Lassa fever for four decades. Ribavirin is a pro-drug, metabolised to its active m...
Príomhchruthaitheoir: | Salam, A |
---|---|
Rannpháirtithe: | Horby, P |
Formáid: | Tráchtas |
Teanga: | English |
Foilsithe / Cruthaithe: |
2024
|
Ábhair: |
Míreanna comhchosúla
-
Two Cases of Lassa Fever Successfully Treated with Ribavirin and Adjunct Dexamethasone for Concomitant Infections
de réir: Sylvanus Okogbenin, et al.
Foilsithe / Cruthaithe: (2022-10-01) -
Ribavirin for Lassa Fever Postexposure Prophylaxis
de réir: Christiane M. Hadi, et al.
Foilsithe / Cruthaithe: (2010-12-01) -
Animal Models of Lassa Fever
de réir: Rachel A. Sattler, et al.
Foilsithe / Cruthaithe: (2020-03-01) -
Addressing bottlenecks in Lassa fever treatment: overcoming the ribavirin parenteral formulation challenge
de réir: Qudus Olajide Lawal, et al.
Foilsithe / Cruthaithe: (2024-07-01) -
Bibliometric analysis of global Lassa fever research (1970–2017): a 47 – year study
de réir: Henshaw Uchechi Okoroiwu, et al.
Foilsithe / Cruthaithe: (2018-12-01)